title: A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
authors.affiliation: Department of Ophthalmology, University of Ehime School of Medicine, Shizukawa, Toon City Ehime, 7910295, Japan. ohashi@m.ehime-u.ac.jp
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ebihara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fujishima
authors.forename: Atsuki
authors.initials: A
authors.lastname: Fukushima
authors.forename: Naoki
authors.initials: N
authors.lastname: Kumagai
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Namba
authors.forename: Shigeki
authors.initials: S
authors.lastname: Okamoto
authors.forename: Jun
authors.initials: J
authors.lastname: Shoji
authors.forename: Etsuko
authors.initials: E
authors.lastname: Takamura
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Hayashi
mesh_terms: D000293:Adolescent; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D018434:Sickness Impact Profile; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016559:Tacrolimus